FDA to Approve Omicron Booster
The FDA is expected to approve Pfizer and Moderna’s updated Covid-19 booster vaccine this week, which covers the dominant BA.5 Omicron subvariant. mRNA technology is remarkable. The BA.5 subvariant started picking up steam back in June, and here we are nearly three months later with a vaccine ready to go. The Deets Pfizer and Moderna’s…
Read MoreHow to Make Outpatient Scheduling More Efficient
An appointment with my dermatologist—that’s who I’m waiting for. I called my dermatologist’s office to make an appointment for a routine body check, hoping to get an appointment in a week or two. “A week or two? The next available appointment is in three months. Which day works best for you?” “But… I don’t know…
Read MoreHow Much do Cancellations and No-shows Cost Your Practice?
Click the button below to access my model that estimates how much your practice is losing annually through inefficient scheduling. Please make a copy of the model to manipulate the inputs. If you plan on sharing the model, please credit me/Healthcare Huddle. Also, if you have any questions, please email me to chat further at…
Read MoreCounting Sheep: Who’s Helping Us Optimize our Sleep?
We spend one-third of our life sleeping. Yet, seldom do we treat our sleep with the respect it deserves. Even in medical school, I can only recall one lecture about sleep, despite concrete evidence that poor sleep leads to morbidity and mortality. Sleep is an attractive market for digital health companies given its important health…
Read MoreGraying America and the Geriatrician Shortage
As my anatomy professor used to say, aging is inevitable and beautiful. But, to ensure we age beautifully, we need the right people to help us—which is the big problem. While the population of adults 65 and older continues to grow, the population of geriatricians—physicians specialized in caring for the complex needs of older adults—isn’t…
Read MoreOutside the Huddle #137
1) Was the Amyloid Hypothesis Wrong? You’ve probably heard of Biogen’s unsuccessful Alzheimer’s drug, Aduhelm. Well, it turns out some of the original research showing that amyloid proteins (the target of Aduhelm) play a role in Alzheimer’s might have been fabricated. According to the investigation, a scientist copied gel lines from gel electrophoresis studies, making…
Read More